A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

Trial Profile

A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Aug 2018

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Bleomycin; Dacarbazine; Doxorubicin; Vinblastine
  • Indications Hodgkin's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms ECHELON-1
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 17 Jun 2018 Results of post-hoc analysis presented at the 23rd Congress of the European Haematology Association.
    • 17 Jun 2018 Results comparing the effects of frontline brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) vs frontline ABVD presented at the 23rd Congress of the European Haematology Association
    • 17 Jun 2018 Results of pre-specified sub-analysis in high risk subgroups presented at the 23rd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top